Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 9, 2020
Daily News
March 9, 2020
- Japan Sets 1st Rollout of Amended PMD Law for Sept. 1
March 9, 2020
- Aducanumab “on Track” for FDA Filing: Eisai CEO
March 9, 2020
- FTC Hits Torii with Cease, Desist, and Surcharge Payment Order over Price-Fixing for Calvan
March 9, 2020
- Japan’s Big 3 Generic Makers See 12.2% Price Cut vs. FY2018: Jiho Poll
March 9, 2020
- FDA Accepts Vibegron for Review; Target Date Set for Dec. 26
March 9, 2020
- Shionogi Boosts Stake in Tetra under Alzheimer's Deal; Buyout on the Cards
March 9, 2020
- PMDA Reviewing Safety Risks for Xofluza, Keytruda
March 9, 2020
- Japan Ethical Drug Sales Down 1.2% in January: Crecon
March 9, 2020
- Large-Scale Clinical Data Confirms Efficacy and Safety of Switch to Vemlidy for Hep B: Gilead
March 9, 2020
- Alvesco Inhibits RNA Replications: NIID
March 9, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…